Literature DB >> 15024701

Amplification of CDK4, MDM2, SAS and GLI genes in leiomyosarcoma, alveolar and embryonal rhabdomyosarcoma.

P Ragazzini1, G Gamberi, L Pazzaglia, M Serra, G Magagnoli, F Ponticelli, C Ferrari, C Ghinelli, M Alberghini, F Bertoni, P Picci, M S Benassi.   

Abstract

We evaluated amplification and overrepresentation of CDK4, MDM2, GLI and SAS genes of the 12q13-15 region, in a group of soft tissue sarcomas including leiomyosarcomas (LMS), alveolar rhabdomyosarcomas (ARMS) and embryonal (anaplastic and classic variants) rhabdomyosarcomas (ERMS), to ascertain genomic alterations and possible differences within histologic subtypes of rhabdomyosarcoma (RMS). Quantitative real-time PCR was performed on DNA samples from 29 LMS, 9 ARMS, 7 anaplastic ERMS and 6 classic ERMS. Alteration of one or more of the 12q13-15 genes was revealed in 13/29 LMS (45%) and 12/22 RMS (54%) including 5/9 ARMS (56%), 5/7 anaplastic ERMS (71%) and 2/6 classic ERMS (33%). The potential importance of overproduction of protein products in neoplastic development, led us also to study a possible high expression of cdk4, mdm2 and gli proteins in immunohistochemical staining experiments on paraffin-embedded tissue samples of the same cases. Among LMS and RMS most cases with CDK4, MDM2 and GLI gene alterations also showed a simultaneous high expression of the relative protein. In summary, these results indicate that amplification or overerepresentation of genes at 12q13-15 region involve both LMS and RMS. Moreover these genes alterations reveal predominantly in the alveolar and in the anaplastic variant of the embryonal subtype. These two seem to have a more similar behavior than anaplastic and classic embryonal that are classified in the same subtype.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15024701     DOI: 10.14670/HH-19.401

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  31 in total

Review 1.  Advances in pediatric rhabdomyosarcoma characterization and disease model development.

Authors:  D O'Brien; A G Jacob; S J Qualman; D S Chandler
Journal:  Histol Histopathol       Date:  2012-01       Impact factor: 2.303

2.  Nutlin-3 down-regulates retinoblastoma protein expression and inhibits muscle cell differentiation.

Authors:  Erica M Walsh; MengMeng Niu; Johann Bergholz; Zhi-Xiong Jim Xiao
Journal:  Biochem Biophys Res Commun       Date:  2015-04-12       Impact factor: 3.575

3.  Target identification for a Hedgehog pathway inhibitor reveals the receptor GPR39.

Authors:  Frederic Bassilana; Adam Carlson; Jennifer A DaSilva; Bianka Grosshans; Solange Vidal; Valerie Beck; Barbara Wilmeringwetter; Luis A Llamas; Todd B Showalter; Pascal Rigollier; Aaron Bourret; Arun Ramamurthy; Xu Wu; Fred Harbinski; Samantha Plonsky; Lac Lee; Heinz Ruffner; Paola Grandi; Markus Schirle; Jeremy Jenkins; Andreas W Sailer; Tewis Bouwmeester; Jeffrey A Porter; Vic Myer; Peter M Finan; John A Tallarico; Joseph F Kelleher; Klaus Seuwen; Rishi K Jain; Sarah J Luchansky
Journal:  Nat Chem Biol       Date:  2014-03-16       Impact factor: 15.040

Review 4.  Probing for a deeper understanding of rhabdomyosarcoma: insights from complementary model systems.

Authors:  Venkatesh P Kashi; Mark E Hatley; Rene L Galindo
Journal:  Nat Rev Cancer       Date:  2015-07       Impact factor: 60.716

Review 5.  Childhood rhabdomyosarcoma: recent advances and prospective views.

Authors:  C Wang
Journal:  J Dent Res       Date:  2011-09-13       Impact factor: 6.116

Review 6.  TP53 in bone and soft tissue sarcomas.

Authors:  Elizabeth Thoenen; Amanda Curl; Tomoo Iwakuma
Journal:  Pharmacol Ther       Date:  2019-07-02       Impact factor: 12.310

7.  Prenatal X-ray exposure and rhabdomyosarcoma in children: a report from the children's oncology group.

Authors:  Seymour Grufferman; Frederick Ruymann; Simona Ognjanovic; Erik B Erhardt; Harold M Maurer
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-17       Impact factor: 4.254

8.  Can HMGI-C be used as an aid with MDM2 and CDK4 to differentiate liposarcoma subtypes from their mimics?

Authors:  Hanan Alshenawy
Journal:  J Cancer Res Clin Oncol       Date:  2013-03-26       Impact factor: 4.553

9.  Common genetic changes in leiomyosarcoma and gastrointestinal stromal tumour: implication for ataxia telangiectasia mutated involvement.

Authors:  Aliya Ul-Hassan; Karen Sisley; David Hughes; David W Hammond; Martin H Robinson; Malcolm W R Reed
Journal:  Int J Exp Pathol       Date:  2009-10       Impact factor: 1.925

10.  Prognostic value of HMGA2, CDK4, and JUN amplification in well-differentiated and dedifferentiated liposarcomas.

Authors:  Esma Saâda-Bouzid; Fanny Burel-Vandenbos; Dominique Ranchère-Vince; Isabelle Birtwisle-Peyrottes; Bruno Chetaille; Corinne Bouvier; Marie-Christine Château; Michel Peoc'h; Maxime Battistella; Audrey Bazin; Jocelyn Gal; Jean-François Michiels; Jean-Michel Coindre; Florence Pedeutour; Laurence Bianchini
Journal:  Mod Pathol       Date:  2015-09-04       Impact factor: 7.842

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.